Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT Combined With CD19 CAR-T for Refractory/Relapsed Malignant Lymphoma
NCT05239676Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T cells in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal large B-cell lymphoma (PMBCL) and 1 more, sponsored by Zhejiang University. Primary endpoints: Overall Response Rate at 30 months and Incidence of Treatment-Emergent Adverse Events at 24 months. Status: unknown.
02
Drugs
CD19 CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT05239676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239676.